article thumbnail

Pharmaceutical Negotiations Decoded: Lessons from the Trenches

Drug Patent Watch

From mergers and acquisitions to licensing agreements and pricing discussions, these complex interactions demand a unique blend of scientific knowledge, business acumen, and interpersonal skills. Intellectual property is often a central issue in pharmaceutical negotiations, particularly in licensing deals and partnerships.

article thumbnail

Gepirone

New Drug Approvals

5] History Gepirone was developed by Bristol-Myers Squibb in 1986, [5] but was out-licensed to Fabre-Kramer in 1993. 5] It was submitted for the preregistration (NDA) phase again in May 2007 after adding additional information from clinical trials as the FDA required in 2009. Schatzberg AF, Nemeroff CB (2009). PMID 37856644.

FDA 62
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bayer Expands Collaboration with Tsinghua University to Boost Pharma R&D in China

The Pharma Data

A Legacy of Collaborative Excellence The relationship between Bayer and Tsinghua University began in 2009 as part of a broader effort by Bayer to establish strong academic linkages in Asia’s rapidly advancing research landscape.

article thumbnail

Unlocking the power of stem cell therapy

Drug Target Review

Dr Scheer earned his medical degree from New York Medical College and subsequently completed his Surgical internship at Mount Sinai Beth Israel, followed by training in neurological surgery at the Albert Einstein College of Medicine until 2009.

Therapies 105
article thumbnail

Elacestrant 

New Drug Approvals

2] [4] Pharmacology Pharmacodynamics Elacestrant is an antiestrogen that acts as an antagonist of estrogen receptors , specifically targeting the estrogen receptor alpha (ER), which is the biological target of endogenous estrogens like estradiol. [1] 1] [8] Pharmacokinetics Elacestrant has an oral bioavailability of approximately 10%. [1]

FDA 62
article thumbnail

Peijia Medical and HighLife Enter Into License and Technology Transfer Agreement for Transeptal Mitral Valve Replacement in Greater China

The Pharma Data

” Under the License Agreement, Peijia and HighLife will establish a joint review committee to enhance a mutual sharing of information about the development as well as commercialization of the TMVR products, further deepening cooperation between the two companies. SUZHOU, China and PARIS , Dec.

article thumbnail

FDA Knows Its Own Strength—and It Includes Concentration

FDA Law Blog: Biosimilars

This of course, make sense—after decades of experience implementing the Hatch-Waxman, Congress and FDA had learned a few new tricks by 2009/2010. To Boehringer’s first and most significant argument, that Congress intended the terms “strength” to match FDA’s interpretation in 2009—prior to the codification of the definition in 21 C.F.R.

FDA 59